PolarityTE Inc.

PolarityTE — Investor Presentation (June 2018)

42 slides from PolarityTE's investor presentation, Jun 7, 2018

  1. Slide 1: PolarityTE: Where Self Regenerates Self

  2. Slide 2: Forward Looking Statements

    FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements and projections. The company makes no express or implied representation or warrant as to the completeness of this information or, in the case of projections, as to their attainability or the accuracy and completeness of

  3. Slide 3: PolarityTE company description

    PolarityTE" A commercial-stage biotechnology and regenerative biomaterials company focused on transforming the lives of patients by delivering a range of functional tissues using our novel platform technology. oe

  4. Slide 4: Ask yourself: name one company or product that truly regenerates anything

    ; Ask yourself—Name one company or product that @ truly regenerates ANYTHING? ae wee - Lg > 4 SS =

  5. Slide 5: Here is where things get cool

    Hore is where things get cool: For the SkinTE process, the surgeon sends the full thickness harvest off to PolarityTE, they grind it up into skin seed jelly (less than technical but you can read all about the medical version on their webpage posted below), and then jelly is returned the next day and

  6. Slide 6: The Problem

    The Problemw a The Tissue Engineering Triad h Regenerative Medicine— Tissue Engineering Tissue Engineered Skin Substitutes ‘and synthetic scaffolds struggle to regenerate complete functionaltissuesand are Tissue engineering triads, single cell suspension, growth factors, monolayercultures ‘often see

  7. Slide 7: Question: What Has Been Missing?

    Question: Has Been Missing? \A a ig _ | : \A/Aat Ks Doalarity Vv \ | tl po-lari-ty: the asymmetric organization of cellular elements, which allows development of specialized tissue and downstream function. (> Poartyle

  8. Slide 8: Functional polarization of SkinTE regenerates full-thickness hair-bearing skin

    The functional polarization of SkinTE is designed to regenerate full-thickness, hair-bearing skin with all of the appendages (hair follicle, glands, etc.) and layered interfaces (epidermis, dermis and hypodermis). We believe the subsequent fullthickness regeneration of SkinTE leads to improved three

  9. Slide 9: PolarityTE - We Design Platform Technologies

    PolarityTE™ - We Design Platform Technologies We believe precise design and development of our Core TE Tissue Systems, utilizing novel Minimally Polarized Functional Units (MPFUs), permits us to regenerate a full spectrum of functionally-polarized complex tissues AUTOLOGOUS- FROM THE PATIENT FOR THE

  10. Slide 10: Our First Full-Thickness, Functionally-Polarized Tissue - SkinTE

    Our First Full-Thickness, Functionally-Polarized Tissue - SkinTE™ From a small piece of tissue to the regeneration, replacement and/or reconstruction of full-thickness, hair-bearing skin Commercially available and in clinical use since December 2017. Intended to be used by physicians and other epbro

  11. Slide 11: SkinTE: Designed to Address Current Critical Unmet Needs

    SkinTE™: Designed to Address Current Critical Unmet Needs | Different Cells and Structures Exist at Different Layers within the Skin—Taking Only Some of them Prevents the Regeneration of Full-Thickness Hair-Bearing Skin SKIN GRAFTS - LIMITED DONOR SKIN NATIVE DONOR SKIN IS LIMITED: Full-thickness au

  12. Slide 12: SkinTE Compared to Commercially Available Skin Substitutes

    kinTE™ Compared to Commercially Available Skin Substitutes SkinTE Skin is much more than a single layer to provide a barrier - itis the largest organ in a the human body and requires regeneration of all components for normal function. “[W]ithout the component of the recipients own distinct epitheliu

  13. Slide 13: The SkinTE Difference: Skin Regenerates Skin

    The SkinTE™ Difference Simply Put—Skin Regenerates Skin Conventional Wound Care Direct Comparison of SkinTE Full-+thickness Hair-bearing Skin Regeneration vs. Native Skin and Wound. Regenerative healing occurs through a process which not only regenerates the appropriate and necessary tissues, functi

  14. Slide 14: The SkinTE Difference - Directs Intelligent & Dynamic Healing

    The SkinTE™ Difference - Directs Intelligent & Dynamic Healing Conventional Wound Therapy Promotes Wound Contraction from the Wound Edges. SkinTE™ Promotes Healing within the Defect, Reducing Contraction and Scar Formation Mid-Stage Native Contracting Wound Marginal Contraction and Migration — Eidel

  15. Slide 15: Full-Thickness Skin Regeneration in Full-Thickness Wounds

    Full-Thickness Skin Regeneration in Full-Thickness Wounds PolarityTE™ Minimally Polarized Function Units Regenerate the Appendages of the Skin—Those Appendages then Regenerate the Full-Thickness Hair-Bearing Skin Structures and Tissues MPFU Regeneration of Appendages within the Skin Drives Direction

  16. Slide 16: Comparing the Clinical Standard of Care to SkinTE

    Comparing the Clinical Standard of Care to SkinTE™ Native Scar Healed Wound | Native Skin Margin _ Native Skin u Full-Thickness Allograft Autogratt \\ Margin Native Skin { Skin defects heal through a process of wound contraction and often scar formation. While skin grafts reduce contraction, patient

  17. Slide 17: Comparing SkinTE to Native Skin

    Native Skin Bn and PeriodicAcid-Schiff. The images and data presented here are from pre-clinical studies ‘Comparing SkinTE™ to Native Skin. Comparative of analysis of ancillary histology between SkinTE™ (left) and native skin (right). Ancillary stains include: Hematoxylin and Eosin, Trichrome | Brew

  18. Slide 18: SkinTE - Commercialization and Staged Growth

    SkinTE™- Commercialization and Staged Growth - ee STAGE 1: Product Development Finalization of the SkinTE product development withthe goal of the easy product to choose and simple product touse STAGE 2: FDA 361 HCT/P Process Verification(s) FDA regulatory processes for verified registrations and sit

  19. Slide 19: SkinTE - Clinical Commercialization and Market Entry

    SkinTE™- Clinical Commercialization and Market Entry ~ —aann . ¢ ASuperior Technology THE Easy Product to Use Reduced Cost to Users Better HCP Reimbursement Complete Product Support & we ‘or Product Supt wi Pry A sai POLARITYE PLATFORM TECHNOLOGY 19.

  20. Slide 20: SkinTE - Early-Stage Healing in Patients

    SkinTE™- Early-Stage Healing in Patients Early Progression of Healing - 7 Week Time Period Th Early Progression of Healing - 4 Week Time Period Early Progression of Healing - 6Week Time Period SkinTE™ was designed and developedtotreata full spectrum of defects and conditions of the skin ina mannerwh

  21. Slide 21: SkinTE Used in Refractory Wounds Where Skin Grafts Fail

    SkinTE™-Used in Refractory Wounds Where Skin Grafts Fail A Case of Two Legs What happens when split-thickness skin grafts (the current clinical standard of care) fail? What happens when both conventional and advanced wound care efforts are unsuccessful? 35-year-old male witha chronic progressive ref

  22. Slide 22: SkinTE - A Regenerative Bioreactor Inside of Tissue Defects

    SkinTE™- A Regenerative Bioreactor Inside of Tissue Defects From the Inside Out SkinTE Expands and Grows on the Best Bioreactor Known to Humankind—The Patient + Conventionally, Progressive Propagation of Melanocyte Pigmentation and Appendages Cell/Tissue Products are cultured, expanded and induced u

  23. Slide 23: SkinTE vs. Skin Grafts

    SkinTE vs. Skin Grafts Skin is more thana sheet of keratinocytes HF Native Skin Skin grafts are incomplete forms of skin and that is why they do not regenerate Relative Pigment Feature Extraction Derma: appendages a * Appendagesare vital z for skin regeneration, i ; z maintenance and a Molecular Fin

  24. Slide 24: SkinTE - Early-Stage Healing and Return of Pigment in Patients

    SkinTE™ - Early-Stage Healing and Return of Pigmentin Patients SkinTE™ was designed and developed totreata full spectrum of defects and conditions of the skin in a manner which truly promotes and utilizes the conceptof self regeneration early on in the healing process —Where Self Regenerates Self™ P

  25. Slide 25: Native Skin SkinTE

    Native Skin SkinTE™ SkinTE Following Replacement of Split-Thickess Skin Graftin Fibrotic WoundBed ConductingPinch Test of SkinTE at 6 months Dermascope Punch Biopsy of SkinTE Depicts All Layers of Full-ThicknessSkinand Appendages Rete Pegs Located at Epidermal /Dermal Junction Prevent ShearSkin [ROI

  26. Slide 26: Targeted Sales (Tier Strategy)

    Targeted Sales (Tier Strategy) Real-Time Assistant(RTA) Advertising, Conferences Barrier Reduction -” Easyas Amazon” Educating on the New Paradigm AUnique Distribution and Sales Strategy Provider Spectrum APRODUCTFOR ALL PROVIDERS AND FACILITIES + Surgeons, Medical Doctors, Physician Assistant, Nurs

  27. Slide 27: Real-Time Assistant App

    PolarityTE™ Real-Time Assistant App A face-to-face consultation with a PolarityTE™ physician 24 hours a day. ANew Way to Communicate and Use PolarityTE™ Products: The PolarityTE™ Real-Time Assistant App fori0S, Android and Computer Systems Allows Peer-to-Peer Support Between Medical Professionals an

  28. Slide 28: Current Markets Remain Underpenetrated

    CURRENT MARKETS REMAIN UNDERPENETRATED Global markets for tissue engineering and regenerative medicine is expected to grow to > $100 billion by 2022, with a five-year CAGR of 26.0% Worldwide prevalence of woundsis exponentially $ Thousands 8 Growth in Worldwide Prevalence of Wound Types, 2011-2020 M

  29. Slide 29: SkinTE Commercialization & Growth

    SkinTE™ Commercialization & Growth A STRATEGIC MARKET RELEASE Staged market release goals for 2018 focus on building a robust foundation of clinical evidence in multiple wound types and practice settings Targeting recognized leaders specializing in reconstructive, wound and burn treatmentas early ad

  30. Slide 30: The Core PolarityTE Product Pipeline

    The Core PolarityTE Product Pipeline Preclinical Development Clinical Development Prototype Modeling Studies Development Pipeline of PolarityTECore “TE” Products. A pipeline chart depicting some of the public core “TE tissue product candidates (defined complex tissue constructs for autologous-homolo

  31. Slide 31: Next Platform Product on the Horizon?

    Next Platform Product onthe Horizon?

  32. Slide 32: OsteoTE - Expected to Launch in Late 2018

    Os sigoTEm'- Expected to Launch in Late 2018 OsteoTE™ is an autologous - from the patient, for the patient - productintended forbone repair, reconstruction, replacement, supplementation and regeneration, including in the long bone, craniomaxillofacial, spine, dental, handand foot/ankle markets. (2)

  33. Slide 33: OsteoTE - Regeneration of Bone in Critical Defects

    OsteoTE™ — Regeneration of Bone in Critical Defects Defect Native (CT) Ss) Week 8 Bd (CT) { vais ‘ieee, ON _ — Surface Pty Comparative Imaging of CLICSAM Substrate in Critical Sized Cranial Defect Model System. (a.) Three dimensional (3-D) micro computed tomography (micro-CT) native cranial bone dis

  34. Slide 34: Comparing OsteoTE to Native Bone and Other Products

    Comparing OsteoTE™ to Native Bone and Other Products JEL Interfaces Drive Vascularized Osteogenesis OsteoTE. oe ative, BONE a. OsteoTE+ BGM OsteoTE+DGAU° Autologous Bone Plate DBM + BMP2 DBM+BMP2 OsteoTE +DGALLO OsteoTE +BGALO OsteoTE © Auto BonePlate Defect Control Native Bone

  35. Slide 35: OsteoTE: Molecular Fingerprinting of Functional Tissues

    TE™: Molecular Fingerprin ve Functional Tissues | Integrative Angiogenesis and Osteogenesis Correlate this with Functional Outcomesand Tissue Fingerprints Osteogenesis Profile Angiogenesis Profile i i ni i 60 f i OsteoTE +86 z so OsteoTE +06. 3 % OsteoTE H z \ Native Bone 4 a q ‘Auto Bone Flap 20 10

  36. Slide 36: The Regeneration of Complex, Hierarchically-Organized Bone

    The Regeneration of Complex, Hierarchically-Organized Bone Osteuiie eMPand tong Bone Pre-Clinical Complete UPDATE: OsteoTE™ Spine Studies Underway, 7 De Saal is, Welcome to the Shift™ ’ o $ J J cas

  37. Slide 37: PolarityTE Executive Management

    PolarityTE Executive Management ‘ley Denver Lough, MD, PhD Chief Executive Officer & Chairman + Iinventor/innovator behind patented PolarityTE™ platform & derivatives *+ Joined PolarityTE from the Department of, Johns Hopkins Piastic and Reconstructive Surgery. MD/PhD Program, Georgetown University

  38. Slide 38: Board of Directors

    Independent Jon Mogford, PhD «ee DenverLough, MD, PhD Chairman & Chief Executive Officer a John Stetson Pe cccininc Vic Present. Chisfnancial Officer, Director 1 Steve Gorlin | Director M Regenerative Medicine and Biotech Pioneer: Founder of Hycor Biomedical, Inc. (acquired by Agilent), Theragenics

  39. Slide 39: The PolarityTEAM - Clinical Advisory Board

    The PolarityTEAM - Clinical Advisory Board

  40. Slide 40: PolarityTE - Welcome to the SHIFT

    PolarityTE™ - Welcometo the SHIFT™ | EVOLVING TECHNOLOGY PLATFORMS AND PRODUCTS — # — Fs Weare a clinical stage, commercial biotechnology and regenerative materials company I Ti tast INNOVATIVE ¢) COMPANIES with new and expanding technology platforms which we believe can be utilized to create i/ fun

  41. Slide 41: About Platform Products

    About Platform Products PolarityTE™ Corporate ————-— Website: www.PolarityTE.com Email: [email protected] Corporate Inquiries: (800) 378-2694 [email protected] NASDAQ Ticker:COOL PolarityTE™ Support Customer Service: (800) 560-3983 [email protected] Medical Af

  42. Slide 42: Slide 42

PolarityTE — Investor Presentation (June 2018) on 6ix